158 related articles for article (PubMed ID: 31390566)
1. A Spontaneous Aggressive ERα+ Mammary Tumor Model Is Driven by Kras Activation.
Campbell KM; O'Leary KA; Rugowski DE; Mulligan WA; Barnell EK; Skidmore ZL; Krysiak K; Griffith M; Schuler LA; Griffith OL
Cell Rep; 2019 Aug; 28(6):1526-1537.e4. PubMed ID: 31390566
[TBL] [Abstract][Full Text] [Related]
2. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer.
Arendt LM; Rugowski DE; Grafwallner-Huseth TA; Garcia-Barchino MJ; Rui H; Schuler LA
Breast Cancer Res; 2011 Jan; 13(1):R11. PubMed ID: 21276249
[TBL] [Abstract][Full Text] [Related]
3. Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes.
Arendt LM; Evans LC; Rugowski DE; Garcia-Barchino MJ; Rui H; Schuler LA
J Endocrinol; 2009 Oct; 203(1):99-110. PubMed ID: 19635758
[TBL] [Abstract][Full Text] [Related]
4. Modeling prolactin actions in breast cancer in vivo: insights from the NRL-PRL mouse.
O'Leary KA; Shea MP; Schuler LA
Adv Exp Med Biol; 2015; 846():201-20. PubMed ID: 25472540
[TBL] [Abstract][Full Text] [Related]
5. Prolactin drives estrogen receptor-alpha-dependent ductal expansion and synergizes with transforming growth factor-alpha to induce mammary tumors in males.
Arendt LM; Schuler LA
Am J Pathol; 2008 Jan; 172(1):194-202. PubMed ID: 18156207
[TBL] [Abstract][Full Text] [Related]
6. Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis.
Jang JW; Boxer RB; Chodosh LA
Mol Cell Biol; 2006 Nov; 26(21):8109-21. PubMed ID: 16908535
[TBL] [Abstract][Full Text] [Related]
7. Prolactin synergizes with canonical Wnt signals to drive development of ER+ mammary tumors via activation of the Notch pathway.
O'Leary KA; Rugowski DE; Shea MP; Sullivan R; Moser AR; Schuler LA
Cancer Lett; 2021 Apr; 503():231-239. PubMed ID: 33472091
[TBL] [Abstract][Full Text] [Related]
8. Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells.
Barcus CE; O'Leary KA; Brockman JL; Rugowski DE; Liu Y; Garcia N; Yu M; Keely PJ; Eliceiri KW; Schuler LA
Breast Cancer Res; 2017 Jan; 19(1):9. PubMed ID: 28103936
[TBL] [Abstract][Full Text] [Related]
9. Prolactin Alters the Mammary Epithelial Hierarchy, Increasing Progenitors and Facilitating Ovarian Steroid Action.
O'Leary KA; Shea MP; Salituro S; Blohm CE; Schuler LA
Stem Cell Reports; 2017 Oct; 9(4):1167-1179. PubMed ID: 28919264
[TBL] [Abstract][Full Text] [Related]
10. Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice.
Rose-Hellekant TA; Arendt LM; Schroeder MD; Gilchrist K; Sandgren EP; Schuler LA
Oncogene; 2003 Jul; 22(30):4664-74. PubMed ID: 12879011
[TBL] [Abstract][Full Text] [Related]
11. Prolactin cooperates with loss of p53 to promote claudin-low mammary carcinomas.
O'Leary KA; Rugowski DE; Sullivan R; Schuler LA
Oncogene; 2014 Jun; 33(23):3075-82. PubMed ID: 23873024
[TBL] [Abstract][Full Text] [Related]
12. Comparative genomics of susceptibility to mammary carcinogenesis among inbred rat strains: role of reduced prolactin signaling in resistance of the Copenhagen strain.
Ren X; Zhang X; Kim AS; Mikheev AM; Fang M; Sullivan RC; Bumgarner RE; Zarbl H
Carcinogenesis; 2008 Jan; 29(1):177-85. PubMed ID: 17916903
[TBL] [Abstract][Full Text] [Related]
13. Alterations in c-Src/HER1 and estrogen receptor α signaling pathways in mammary gland and tumors of hexachlorobenzene-treated rats.
Peña D; Pontillo C; García MA; Cocca C; Alvarez L; Chiappini F; Bourguignon N; Frahm I; Bergoc R; Kleiman de Pisarev D; Randi A
Toxicology; 2012 Mar; 293(1-3):68-77. PubMed ID: 22245120
[TBL] [Abstract][Full Text] [Related]
14. Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice.
Wennbo H; Gebre-Medhin M; Gritli-Linde A; Ohlsson C; Isaksson OG; Törnell J
J Clin Invest; 1997 Dec; 100(11):2744-51. PubMed ID: 9389738
[TBL] [Abstract][Full Text] [Related]
15. Prolactin potentiates transforming growth factor alpha induction of mammary neoplasia in transgenic mice.
Arendt LM; Rose-Hellekant TA; Sandgren EP; Schuler LA
Am J Pathol; 2006 Apr; 168(4):1365-74. PubMed ID: 16565509
[TBL] [Abstract][Full Text] [Related]
16. Prolactin gene-disruption arrests mammary gland development and retards T-antigen-induced tumor growth.
Vomachka AJ; Pratt SL; Lockefeer JA; Horseman ND
Oncogene; 2000 Feb; 19(8):1077-84. PubMed ID: 10713693
[TBL] [Abstract][Full Text] [Related]
17. Conditional expression of Ki-Ras
Andò S; Malivindi R; Catalano S; Rizza P; Barone I; Panza S; Rovito D; Emprou C; Bornert JM; Laverny G; Metzger D
Oncogene; 2017 Nov; 36(46):6420-6431. PubMed ID: 28745321
[TBL] [Abstract][Full Text] [Related]
18. A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome.
Hachim IY; Shams A; Lebrun JJ; Ali S
Hum Pathol; 2016 Jul; 53():142-52. PubMed ID: 26980025
[TBL] [Abstract][Full Text] [Related]
19. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations.
D'Cruz CM; Gunther EJ; Boxer RB; Hartman JL; Sintasath L; Moody SE; Cox JD; Ha SI; Belka GK; Golant A; Cardiff RD; Chodosh LA
Nat Med; 2001 Feb; 7(2):235-9. PubMed ID: 11175856
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice.
Mangues R; Corral T; Kohl NE; Symmans WF; Lu S; Malumbres M; Gibbs JB; Oliff A; Pellicer A
Cancer Res; 1998 Mar; 58(6):1253-9. PubMed ID: 9515813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
